0001567619-20-018012.txt : 20201020 0001567619-20-018012.hdr.sgml : 20201020 20201020170009 ACCESSION NUMBER: 0001567619-20-018012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201020 FILED AS OF DATE: 20201020 DATE AS OF CHANGE: 20201020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Woiwode Thomas CENTRAL INDEX KEY: 0001619294 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39617 FILM NUMBER: 201248813 MAIL ADDRESS: STREET 1: ONE SANSOME STREET STREET 2: SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aligos Therapeutics, Inc. CENTRAL INDEX KEY: 0001799448 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (800) 466-6059 MAIL ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2020-10-20 0 0001799448 Aligos Therapeutics, Inc. ALGS 0001619294 Woiwode Thomas C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2020-10-20 4 C 0 2145991 A 2145991 I See footnote Common Stock 2020-10-20 4 C 0 198839 A 2344830 I See footnote Common Stock 2020-10-20 4 C 0 85065 A 2429895 I See footnote Common Stock 2020-10-20 4 C 0 463959 A 463959 I See footnote Common Stock 2020-10-20 4 C 0 198485 A 662444 I See footnote Common Stock 2020-10-20 4 P 0 200000 15 A 862444 I See footnote Series A Preferred Stock 2020-10-20 4 C 0 2145991 0.00 D Common Stock 2145991 0 I See Footnote Series B-1 Preferred Stock 2020-10-20 4 C 0 198839 0.00 D Common Stock 198839 0 I See Footnote Series B-1 Preferred Stock 2020-10-20 4 C 0 463959 0.00 D Common Stock 463959 0 I See Footnote Series B-2 Preferred Stock 2020-10-20 4 C 0 85065 0.00 D Common Stock 85065 0 I See Footnote Series B-2 Preferred Stock 2020-10-20 4 C 0 198485 0.00 D Common Stock 198485 0 I See Footnote Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. These securities are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the sole general partner of VVC VI. Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the sole general partner of VV VI GP and may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV VI GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV VI GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. These securities are held of record by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the sole general partner of VV I. Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of VV I GP and may be deemed to have voting and investment power over the securities held by VV I and as a result may be deemed to have beneficial ownership over such securities. The reporting person is a Managing Director of VV I GP-GP and may be deemed to indirectly beneficially own the securities through his interest in VV I GP-GP. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. /s/ Lucinda Y. Quan, as attorney-in fact for Thomas Woiwode 2020-10-20